Entero Therapeutics, Earnings Per Share vs. Shares Outstanding
| ENTO Stock | 0.47 0.01 2.17% |
For Entero Therapeutics, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Entero Therapeutics, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Entero Therapeutics, utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Entero Therapeutics,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Entero Therapeutics, over time as well as its relative position and ranking within its peers.
Entero |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Entero Therapeutics, Shares Outstanding vs. Earnings Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Entero Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Entero Therapeutics, value to that of its competitors to determine the firm's financial worth. Entero Therapeutics, is one of the top stocks in earnings per share category among its peers. It also is one of the top stocks in shares outstanding category among its peers . As of the 2nd of December 2024, Common Stock Shares Outstanding is likely to grow to about 353.2 K. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Entero Therapeutics,'s earnings, one of the primary drivers of an investment's value.Entero Shares Outstanding vs. Earnings Per Share
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Entero Therapeutics, |
| = | (11.04) X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Entero Therapeutics, |
| = | 3.25 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Entero Shares Outstanding Comparison
Entero Therapeutics, is currently under evaluation in shares outstanding category among its peers.
Entero Therapeutics, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Entero Therapeutics,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Entero Therapeutics, will eventually generate negative long term returns. The profitability progress is the general direction of Entero Therapeutics,'s change in net profit over the period of time. It can combine multiple indicators of Entero Therapeutics,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -19.9 K | -20.9 K | |
| Interest Income | 2.5 K | 3.5 K | |
| Operating Income | -15.8 M | -16.6 M | |
| Net Loss | -15.8 M | -16.6 M | |
| Income Before Tax | -15.8 M | -16.6 M | |
| Total Other Income Expense Net | -24.2 K | -25.4 K | |
| Net Loss | -15.8 M | -16.6 M | |
| Income Tax Expense | 326.4 K | 310 K | |
| Net Loss | (46.96) | (49.31) | |
| Income Quality | 0.78 | 0.50 | |
| Net Income Per E B T | 721.00 | 640.89 |
Entero Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Entero Therapeutics,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Entero Therapeutics, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Entero Therapeutics,'s important profitability drivers and their relationship over time.
Use Entero Therapeutics, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Entero Therapeutics, Pair Trading
Entero Therapeutics, Pair Trading Analysis
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Entero Therapeutics, position
In addition to having Entero Therapeutics, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
To fully project Entero Therapeutics,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Entero Therapeutics, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Entero Therapeutics,'s income statement, its balance sheet, and the statement of cash flows.